Notice of Intent to Sole Source – Therakos, Inc.
ID: 24-013006Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Surgical and Medical Instrument Manufacturing (339112)

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Original Source

https://sam.gov/opp/b0c00c34934546abb3d51c744459f431/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Therakos, Inc. for the urgent procurement of Uvadex (methoxsalen) Sterile Solution for the NIH Clinical Center's Central Pharmacy. This acquisition is critical for providing necessary pharmaceutical supplies, specifically 20 mcg/mL Uvadex in cartons, to meet immediate healthcare needs. The contract will be awarded under the Simplified Acquisition Procedures, allowing for a sole source determination due to the urgency of the requirement. Interested parties may express their interest and capabilities to Kristin Nagashima at kristin.nagashima@nih.gov by September 10, 2024, at 3 PM EST.

    Point(s) of Contact
    Kristin Nagashima
    kristin.nagashima@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Sole Source – Therakos, Inc.
    Currently viewing
    Special Notice
    Similar Opportunities
    Good Manufacturing Practice (GMP)-manufactured Monoclonal Antibody
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to award a sole source contract for the procurement of Good Manufacturing Practice (GMP)-manufactured Monoclonal Antibody UB-421, with a requirement of 100 liters. This procurement is critical for an ongoing clinical trial aimed at treating patients with multidrug-resistant HIV-1 infection, utilizing UB-421, which is exclusively manufactured by United BioPharma, Inc., the sole patent holder and provider of the necessary cell line for production. Interested parties who believe they can meet the specifications must submit a capability statement to the primary contact, Hershea Vance, by 3:00 PM EST on September 20, 2024, as the contract is expected to be awarded within 19 days of this notice, with a performance period from September 23, 2024, to September 24, 2025.
    Notice of Intent to Sole Source – Medtronic
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to award a sole source contract to Medtronic USA, Inc. for the procurement of Concerto Coils and Vascular Plug Systems essential for patient care at the NIH Clinical Center in Bethesda, Maryland. The acquisition includes specific product numbers and quantities, highlighting the unique features of these medical devices that are critical for the clinical needs of the facility. This procurement is being conducted under the Federal Acquisition Regulation (FAR) Part 13, allowing for a sole source award due to the specialized nature of the products. Interested parties may express their interest and capabilities to Kristin Nagashima at kristin.nagashima@nih.gov by September 17, 2024, at 8 AM EST.
    NIEHS - Exodus H-600
    Active
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS) intends to negotiate a sole-source contract with Exodus Bio, Inc. for the acquisition of an Exodus H-600 automatic exosome isolation system. This procurement aims to enhance the NIEHS's capabilities in biological product manufacturing, specifically focusing on the isolation of exosomes, which are critical for various research applications in environmental health. The contract, associated with NAICS Code 325414, is expected to include one unit of the specified equipment, with a delivery timeframe of 60 days post-award. Interested parties capable of fulfilling this requirement are encouraged to submit a capability statement via email by September 18, 2024, and inquiries can be directed to Tanya Redfearn at shields3@niehs.nih.gov or by phone at 984-287-3052.
    Notice of Intent - Ortho Clinical Reagents and Supplies
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to award a fixed-price contract for Ortho Clinical reagents and supplies, specifically for the Department of Transfusion Medicine at the NIH Clinical Center in Bethesda, Maryland. This procurement aims to secure essential analyzer supplies and reagents that are critical for ensuring the safety and effectiveness of blood products used in transfusion therapy, which must meet specific compatibility requirements for patient treatment. The selected supplier, Ortho-Clinical Diagnostics, Inc., is the sole source for these unique reagents, which have undergone extensive validation studies and are necessary for compatibility testing of both patients and blood donors. Interested parties capable of providing similar products may submit a capability statement by September 22, 2024, to Sheri Eiri at sheri.eiri@nih.gov, as the contract is contingent upon the availability of FY2025 funding.
    Terason uSmart Ultrasound System brand name or equal
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of a Terason uSmart Ultrasound System, or an equivalent product, to enhance clinical and research capabilities in neuromuscular disorders, particularly for pediatric patients. The system must be lightweight, portable, and feature rapid boot-up, image optimization, and comprehensive data storage to meet the needs of the NIH's National Institute of Neurological Disorders and Stroke (NINDS). This acquisition is part of the government's efforts to advance medical research while adhering to federal procurement standards, with a firm-fixed price purchase order anticipated and delivery expected within 30-60 days. Interested small businesses must submit their proposals electronically by September 17, 2024, to Frederick Weddington at frederick.weddington@nih.gov, with inquiries directed to his office at 301-594-6835.
    Intent to Sole Source RS Means Software
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to negotiate a sole source contract with The Gordian Group, Inc. for the licensing of RS Means Software. This software is essential for enhancing the accuracy and efficiency of the NIH's construction cost estimation processes, providing reliable and up-to-date cost data critical for project planning and budgeting. The acquisition of RS Means is vital for ensuring precise estimates that reflect current market trends, thereby reducing the risk of cost overruns and improving overall project management. Interested parties that believe they can meet these requirements must respond within five days of the notice, providing necessary company information, as the contract is set to be awarded as a firm-fixed-price purchase order for a one-year period, from September 23, 2024, to September 22, 2025. For further inquiries, contact Amanda Tilton at amanda.tilton@nih.gov or call 301-594-5711.
    Amendment No. 1 -Notice of Intent to Award a Sole Source Contract – Radiation Protection Advancing Patient Safety
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), intends to award a Sole Source contract to the National Council on Radiation Protection and Measurements (NCRP) for the project titled "Radiation Protection Advancing Patient Safety." The primary objective of this procurement is to obtain up to six well-sourced scientific analyses, reports, and recommendations on radiation safety, which will inform regulatory decision-making and policy development related to radiological medical devices and radiation-emitting electronic products. This initiative is crucial for enhancing patient safety by ensuring that radiation exposure is minimized and that the quality of patient care is improved. Interested parties must submit their capability statements to Bernice Nelson by September 19, 2024, with the contract being executed under simplified acquisition procedures and the NAICS code 541720, which has a small business size standard of $28 million.
    INTENT TO SOLE SOURCE - CAREFUSION for Pyxis rental with full support
    Active
    Health And Human Services, Department Of
    Special Notice: HEALTH AND HUMAN SERVICES, DEPARTMENT OF intends to negotiate a sole source contract with CareFusion Solutions for Pyxis rental with full support. Pyxis is a drug automated distribution system that controls the availability, access distribution, and patient safety. The contract will be in effect from the date of award to March 31, 2025. This is a non-competitive procurement based on exclusive licensing agreement. Other potential sources may submit a capability statement by July 24th, 2024.
    ThermoFisher branded Invitrogen ProcartaPlex immunoassay kits (Brand Name restriction)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for ThermoFisher branded Invitrogen ProcartaPlex immunoassay kits as part of a combined synopsis/solicitation. The procurement aims to acquire specific immunoassay kits necessary for testing human cytokine and chemokine levels in serum and saliva samples from individuals with alcohol use disorder, which is critical for ongoing research into the effects of alcohol consumption on health. The required kits must be capable of detecting and quantifying a panel of 80 targets simultaneously and are essential for ensuring continuity and comparability across various studies conducted by the NIH Clinical Center. Interested vendors must submit their offers by September 17, 2024, to Lu Chang at lu-chang.lu@nih.gov, including pricing and delivery timelines, as late submissions will not be considered.
    Using humanized mouse models of NNMT and SULT1A1 for follow-up efficacy studies
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Center for Advancing Translational Sciences (NCATS), intends to award a sole-source contract to GemPharmatech, LLC for follow-up efficacy studies utilizing humanized mouse models of NNMT and SULT1A1. The primary objective of this procurement is to conduct a series of studies, including a Maximum Tolerated Dose (MTD) study, a pharmacokinetic (PK) study, and an efficacy study, to evaluate small molecule inhibitors developed by NCATS, necessitating the creation of mouse models that express human versions of the enzymes involved. This research is critical for advancing the development of therapeutics targeting various human diseases, and the project is expected to span 12 months. Interested parties may submit their capabilities by September 17, 2024, to Michelle Cecilia at michelle.cecilia@nih.gov, with the contract value and specific funding details not disclosed in the announcement.